ACY3: A Promising Drug Target and Biomarker for Acyl-CoA Synthesis and Disorders

Target Name: ACY3

NCBI ID: G91703

ACY3

ACY3: A Promising Drug Target and Biomarker for Acyl-CoA Synthesis and Disorders

The acyl-coenzyme A (acyl-CoA) cycle is a central metabolic pathway that plays a crucial role in the synthesis of essential fatty acids, ketones, and other molecules from the essential amino acids. The acyl-CoA cycle is also involved in the synthesis of many lipids, including fatty acids, which are essential for maintaining cellular membrane structure and function. One of the key enzymes participating in the acyl-CoA cycle is Aminoacylase 3 (ACY3), a protein that catalyzes the conversion of long-chain fatty acids to shorter-chain fatty acids. In this article, we will discuss ACY3 as a drug target and biomarker for various disorders related to acyl-CoA synthesis and metabolism.

The Acyl-CoA Synthesis Cycle

The acyl-CoA synthesis cycle is a complex metabolic pathway that involves the transfer of a carbon atom from the amino acid side chain to the carbonyl group (C=O) of theacyl-CoA molecule. The cycle consists of three main stages: initiation, intermediate, and termination.

Initiation: The first stage of the acyl-CoA synthesis cycle involves the conversion of the amino acid side chain to an amino acid that can accept a carbon atom. This stage is critical for the synthesis of the first acyl-CoA, which is then further processed to form long-chain fatty acids.

Intermediate: The second stage of the acyl-CoA synthesis cycle involves the transfer of the carbon atom from the amino acid side chain to the carbonyl group of the acyl-CoA molecule. This stage is catalyzed by ACY3, which introduces a reactive oxygen species (ROS) to the carbonyl group, which then reacts with the amino acid side chain to form the second acyl-CoA.

Termination: The third stage of the acyl-CoA synthesis cycle involves the formation of the final acyl-CoA by the reaction of the second acyl-CoA with an amino acid that cannot accept a carbon atom. This stage is also critical for the synthesis of long-chain fatty acids.

ACY3: A Potential Drug Target

The acyl-CoA synthesis cycle is a crucial pathway for the synthesis of essential fatty acids and other molecules, and alterations in the acyl-CoA synthesis cycle have been implicated in various diseases. One of the key proteins involved in the acyl-CoA synthesis cycle is ACY3, which has been identified as a potential drug target for various disorders related to acyl-CoA synthesis and metabolism.

ACY3 Activation and Inhibition

The activation of ACY3 has been shown to promote the synthesis of long-chain fatty acids and contribute to the pathogenesis of various diseases, such as obesity, type 2 diabetes, and cardiovascular disease. This is achieved by the introduction of reactive oxygen species (ROS) to the carbonyl group of ACY3, which then reacts with the amino acid side chain to form the second acyl-CoA.

The inhibition of ACY3 has been shown to be a potential therapeutic approach for treating various disorders related to acyl-CoA synthesis and metabolism. By inhibiting ACY3, researchers have observed that the acyl-CoA synthesis cycle is disrupted, leading to a decrease in the synthesis of long-chain fatty acids and an improvement in cellular metabolism.

Biomarkers for ACY3

The acyl-CoA synthesis cycle is a critical pathway for the synthesis of essential fatty acids, which are essential for various cellular functions. Therefore, the expression and function of ACY3 are critical for the diagnosis and treatment of disorders related to acyl-CoA synthesis and metabolism.

Studies have shown that AC

Protein Name: Aminoacylase 3

Functions: Plays an important role in deacetylating mercapturic acids in kidney proximal tubules. Also acts on N-acetyl-aromatic amino acids (By similarity)

The "ACY3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACY3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets